xRNANucleic Acid Drug Development and Innovation Forum
The development of nucleic acid drugs has been tumultuous but has finally borne fruit, being widely used in the treatment of genetic diseases, tumors, viral infections, and other diseases. Small nucleic acid drugs have significant advantages, including rapid target screening, high success rates in research and development, resistance to development, a wider range of therapeutic areas, and long-lasting effects.mRNAVaccines are also developing rapidly against the backdrop of the COVID-19 pandemic. WithmRNAIn vitro synthesis and delivery technology are mature,mRNAThe stability and translation efficiency of drugs have been significantly improved, mainly in the field of vaccines. In addition,mRNAImmunotherapy,Protein replacement therapy,Cell therapy,There is great potential for applications in fields such as regenerative medicine. According to predictionsmRNAThe total market scale is in2035Will reach in230billion dollars.
2024year1month16day-17day,xRNAThe Nucleic Acid Drug Development and Innovation Forum was held in Suzhou, bringing together experts in nucleic acid vaccine and drug research and development from home and abroad, focusing on the new generationmRNA/circ RNAVaccines, drugs, oligonucleotide drug development, preclinical and clinical research, delivery technology and process development are accelerating the industrialization and marketization process.
Frost & SullivanFrost & SullivanGuo Jing, Senior Consulting Director of the Life Sciences Business Unit of Frost & Sullivan's Greater China Region, was invited to attend the meetingmRNASpecial Forum on Vaccine and Drug R&D, focusing onmRNADelivered a keynote speech on "The Current Situation and Development Trends of the Pharmaceutical Market".
Senior Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Guo Jing
Guo Jing pointed out,mRNAThe drug has high R&D efficiency, a simple production process, and can be extended to a wide range of disease areas, making it an innovative therapy. Currently, it is already available globally.8modelmRNAVaccine approved, domestic manufacturermRNAVaccine research and development has also made progress. Along with COVID-19mRNAThe wave of vaccine research and development is prompting domestic and international pharmaceutical companies to actively exploremRNADrug frontier technologies, with indications gradually expanding into the field of non-communicable disease prevention. In the future, based onmRNAThe anti-cancer therapy may change the direction of cancer treatment. Guo Jing stated that driven by factors such as key technological breakthroughs, multi-party R&D cooperation, and policy support,mRNAThe pharmaceutical market has great potential for development.
According to a Frost & Sullivan study, there are currently162modelmRNAThe drug is in clinical development, mainly comprisingmRNAvaccines, and mostmRNAThe drug is still inIperiod andIIPhase clinical stage. In terms of therapeutic domains,mRNAThe drugs under clinical research mainly focus on infectious diseases, oncology, and other fields.LNPThe most widely used delivery system. "mRNAThe drug production process is simple and fast, with the upstream and downstream industries of the industrial chain becoming increasingly mature. In the future, as the R&D system gradually becomes complete and technological applications mature,mRNAThe pharmaceutical market in the treatment sector will continue to expand, and the industry will achieve synchronous development, realizing commercial cooperation." Guo Jing said.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices, which has attracted widespread attention from investors.
